PVLA Share Price Performance
US$123.46
99.48 (414.85%)
Price US$123.46
Share Pricen/a
Palvella Therapeutics, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
PVLA Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Palvella Therapeutics, Inc. Key Details
About PVLA
- Founded
- n/a
- Employees
- 29
- CEO
- WebsiteView website
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
